XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina July 27, 2021
TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit July 22, 2021
Sitryx Licenses Intellectual Property Rights for Inhibitors of a New Target in Immunometabolism from Cancer Research UK in Exclusive Worldwide Agreement July 12, 2021
ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics June 23, 2021
